Fusarium infection in lung transplant patients: Report of 6 cases and review of the literature

Medicine

Volumn 90, Issue 1, 2011, Pages 69-80

  Carneiro, Herman A ^a   Coleman, Jeffrey J ^a   Restrepo, Alejandro ^a   Mylonakis, Eleftherios ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; COTRIMOXAZOLE; ECHINOCANDIN; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ADULT; BLOOD CULTURE; CLINICAL ARTICLE; COUGHING; DRUG MEGADOSE; DYSPNEA; FEMALE; FEVER; FUNGUS CULTURE; FUSARIOSIS; FUSARIUM; GRAFT RECIPIENT; GRANULOCYTOSIS; HEADACHE; HEMOPTYSIS; HUMAN; IMMUNE STATUS; IMMUNOCOMPROMISED PATIENT; INFECTION RISK; LEUKOCYTOSIS; LUNG LAVAGE; LUNG MYCOSIS; LUNG TRANSPLANTATION; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RECOMMENDED DRUG DOSE; REVIEW; SPUTUM CULTURE;

ADULT; AGED; ANTIFUNGAL AGENTS; BRONCHOALVEOLAR LAVAGE; FEMALE; FUNGEMIA; FUSARIUM; HUMANS; IMMUNOCOMPROMISED HOST; LUNG DISEASES, FUNGAL; LUNG TRANSPLANTATION; MALE; MASSACHUSETTS; MIDDLE AGED; SPUTUM;

EID: 78651260037     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/MD.0b013e318207612d     Document Type: Review

References (131)

1. Aguilar-Guisado M, Givalda J, Ussetti P, Ramos A, Morales P, Blanes M, Bou G, de la Torre-Cisneros J, Roman A, Borro JM, Lama R, Cisneros JM. Pneumonia after lung transplantation in the RESITRA cohort: a multicenter prospective study. Am J Transplant. 2007;7:1989-1996.
2. Al-Abdely HM. Management of rare fungal infections. Curr Opin Infect Dis. 2004;17:527-532.
3. Alastruey-Izquierdo A, Cuenca-Estrella M, Monzon A, Mellado E, Rodriguez-Tudela JL. Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. J Antimicrob Chemother. 2008;61:805-809.
4. Anaissie E, Kantarjian H, Jones P, Barlogie B, Luna M, Lopez-Berestein G, Bodey GP. Fusarium. A newly recognized fungal pathogen in immunosuppressed patients. Cancer. 1986;57:2141-2145.
5. Anaissie E, Kantarjian H, Ro J, Hopfer R, Rolston K, Fainstein V, Bodey G. The emerging role of Fusarium infections in patients with cancer. Medicine (Baltimore). 1988;67:77-83.
6. Anaissie EJ, Hachem R, Legrand C, Legenne P, Nelson P, Bodey GP. Lack of activity of amphotericin B in systemic murine fusarial infection. J Infect Dis. 1992;165:1155-1157.
7. Anaissie EJ, Kuchar RT, Rex JH, Francesconi A, Kasai M, Muller FM, Lozano-Chiu M, Summerbell RC, Dignani MC, Chanock SJ, Walsh TJ. Fusariosis associated with pathogenic fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis. 2001;33:1871-1878.
8. Aperis G, Mylonakis E. Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opin Investig Drugs. 2006;15:579-602.
9. Arney KL, Tiernan R, Judson MA. Primary pulmonary involvement of Fusarium solani in a lung transplant recipient. Chest. 1997;112: 1128-1130.
10. Aspergillus Testing: Antibody, EPH, Galactomannan. Department of Pathology, Miller School of Medicine at the University of Miami Web site. Ehttp://www.pathology.med.miami.edu/x143.xml. Accessed on April 12, 2010.
11. Azor M, Gene J, Cano J, Sutton DA, Fothergill AW, Rinaldi MG, Guarro J. In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum. Antimicrob Agents Chemother. 2008;52:2228-2231.
12. Baldwin JE, Wraight EP. Indium labelled leucocyte scintigraphy in occult infection: a comparison with ultrasound and computed tomography. Clin Radiol. 1990;42:199-202.
13. Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs. 2004;64:1997-2020.
14. Bourguignon RL, Walsh AF, Flynn JC, Baro C, Spinos E. Fusarium species osteomyelitis. Case report. J Bone Joint Surg Am. 1976;58:722-723.
15. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years experience at a cancer center and implications for management. Blood. 1997;90:999-1008.
16. Bueno JG, Martinez C, Zapata B, Sanclemente G, Gallego M, Mesa AC. In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis. Clin Exp Dermatol. 2010;35:658-663. Epub. 2009 Oct 23.
17. Campos S, Caramori M, Teixeira R, Afonso J Jr, Carraro R, Strabelli T, Samano M, Pego-Fernandes P, Jatene F. Bacterial and fungal pneumonias after lung transplantation. Transplant Proc. 2008;40:822-824.
18. Caplin I, Unger DL. Molds on the Southern California deserts. Ann Allergy. 1983;50:260-263.
19. Chen HY, Chen YC. Characterization of intact Penicillium spores by matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun Mass Spectrom. 2005;19:3564-3568.
20. Chryssanthou E, Cherif H, Petrini B, Kalin M, Bjorkholm M. Surveillance of triazole susceptibility of colonizing yeasts in patients with haematological malignancies. Scand J Infect Dis. 2004;36:855-859.
21. Cooper JD, Patterson GA, Grossman R, Maurer J. Double-lung transplant for advanced chronic obstructive lung disease. Am Rev Respir Dis. 1989;139:303-307.
22. Cornely OA. Aspergillus to Zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections. Infection. 2008;36:296-313.
23. Cornely OA, Bohme A, Buchheidt D, Einsele H, Heinz WJ, Karthaus M, Krause SW, Kruger W, Maschmeyer G, Penack O, Ritter J, Ruhnke M, Sandherr M, Sieniawski M, Vehreschild JJ, Wolf HH, Ullmann AJ. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica. 2009;94:113-122.
24. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348-359.
25. Denning DW. Echinocandin antifungal drugs. Lancet. 2003;362:1142-1151.
26. Doczi I, Gyetvai T, Kredics L, Nagy E. Involvement of Fusarium spp. in fungal keratitis. Clin Microbiol Infect. 2004;10:773-776.
27. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol. 2003;20:121-136.
28. Evans J, Levesque D, de Lahunta A, Jensen HE. Intracranial fusariosis: a novel cause of fungal meningoencephalitis in a dog. Vet Pathol. 2004;41:510-514.
29. Fleming RV, Walsh TJ, Anaissie EJ. Emerging and less common fungal pathogens. Infect Dis Clin North Am. 2002;16: 915-933.
30. Gabriele P, Hutchins RK. Fusarium endophthalmitis in an intravenous drug abuser. Am J Ophthalmol. 1996;122:119-121.
31. Gallagher JC, MacDougall C, Ashley ES, Perfect JR. Recent advances in antifungal pharmacotherapy for invasive fungal infections. Expert Rev Anti Infect Ther. 2004;2:253-268.
32. Gordon SM, Avery RK. Aspergillosis in lung transplantation: incidence, risk factors, and prophylactic strategies. Transpl Infect Dis. 2001;3:161-167.
33. Guarro J, Gene J. Opportunistic fusarial infections in humans. Eur J Clin Microbiol Infect Dis. 1995;14:741-754.
34. Guinea J, Pelaez T, Recio S, Torres-Narbona M, Bouza E. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother. 2008;52:1396-1400.
35. Guinvarc'h A, Guilbert L, Marmorat-Khuong A, Lavarde V, Chevalier P, Amrein C, Guillemain R, Berrebi A. Disseminated Fusarium solani infection with endocarditis in a lung transplant recipient. Mycoses. 1998;41:59-61.
36. Hachem RR. Lung transplantation: An overview. UpToDate.com Web site. [http://www.uptodateonline.com/patients/content/topic.do? topicKey= ∼A6G8pzUei/zJ4x&selectedTitle=2∼145&source=search-result. Accessed on April 12, 2010.]
37. Hardy JD, Webb WR, Dalton ML Jr, Walker GR Jr. Lung homotransplantation in man. JAMA. 1963;186:1065-1074.
38. Hayden RT, Isotalo PA, Parrett T, Wolk DM, Qian X, Roberts GD, Lloyd RV. In situ hybridization for the differentiation of Aspergillus, Fusarium, and Pseudallescheria species in tissue section. Diagn Mol Pathol. 2003;12:21-26.
39. Healy M, Reece K, Walton D, Huong J, Frye S, Raad II, Kontoyiannis DP. Use of the Diversi Lab System for species and strain differentiation of Fusarium species isolates. J Clin Microbiol. 2005;43:5278-5280.
40. Hennequin C, Abachin E, Symoens F, Lavarde V, Reboux G, Nolard N, Berche P. Identification of Fusarium species involved in human infections by 28S rRNA gene sequencing. J Clin Microbiol. 1999;37:3586-3589.
41. Herbrecht R, Kessler R, Kravanja C, Meyer MH, Waller J, Letscher-Bru V Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipient. J Heart Lung Transplant. 2004;23:1451-1454.
42. Ho DY, Lee JD, Rosso F, Montoya JG. Treating disseminated fusariosis: amphotericin B, voriconazole or both? Mycoses. 2007;50:227-331.
43. Hosseini-Moghaddam SM, Husain S. Fungi and molds following lung transplantation. Semin Respir Crit Care Med. 31:222-233.
44. Hue FX, Huerre M, Rouffault MA, de Bievre C. Specific detection of fusarium species in blood and tissues by a PCR technique. J Clin Microbiol. 1999;37:2434-2438.
45. Husain S, Zaldonis D, Kusne S, Kwak EJ, Paterson DL, McCurry KR. Variation in antifungal prophylaxis strategies in lung transplantation. Transpl Infect Dis. 2006;8:213-218.
46. Jakle C, Leek JC, Olson DA, Robbins DL. Septic arthritis due to Fusarium solani. J Rheumatol. 1983;10:151-153.
47. Kerr CM, Perfect JR, Craven PC, Jorgensen JH, Drutz DJ, Shelburne JD, Gallis HA, Gutman RA. Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Ann Intern Med. 1983;99:334-336.
48. Khan ZU, Ahmad S, Theyyathel AM. Diagnostic value of DNA and (1-3)- beta-D-glucan detection in serum and bronchoalveolar lavage of mice experimentally infected with Fusarium oxysporum. J Med Microbiol. 2008;57:36-42.
49. Kiehn TE, Nelson PE, Bernard EM, Edwards FF, Koziner B, Armstrong D. Catheter-associated fungemia caused by Fusarium chlamydosporum in a patient with lymphocytic lymphoma. J Clin Microbiol. 1985;21:501-504.
50. Kontoyiannis DP, Lewis RE. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect Dis Clin North Am. 2006;20:581-607.
51. Kubak BM. Fungal infection in lung transplantation. Transpl Infect Dis. 2002;4(Suppl 3):24-31.
52. Kurien M, Anandi V, Raman R, Brahmadathan KN. Maxillary sinus fusariosis in immunocompetent hosts. J Laryngol Otol. 1992;106:733-736.
53. Kwon DS, Mylonakis E. Posaconazole: a new broad-spectrum antifungal agent. Expert Opin Pharmacother. 2007;8:1167-1178.
54. Lewis R, Hogan H, Howell A, Safdar A. Progressive fusariosis: unpredictable posaconazole bioavailability, and feasibility of recombinant interferon-gamma plus granulocyte macrophage-colony stimulating factor for refractory disseminated infection. Leuk Lymphoma. 2008;49:163-165.
55. Li TY, Liu BH, Chen YC. Characterization of Aspergillus spores by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom. 2000;14:2393-2400.
56. Liu K, Howell DN, Perfect JR, Schell WA. Morphologic criteria for the preliminary identification of Fusarium, Paecilomyces, and Acremonium species by histopathology. Am J Clin Pathol. 1998;109:45-54.
57. Lupinetti FM, Giller RH, Trigg ME. Operative treatment of Fusarium fungal infection of the lung. Ann Thorac Surg. 1990;49:991-992.
58. Madhavan M, Ratnakar C, Veliath AJ, Kanungo R, Smile SR, Bhat S. Primary disseminated fusarial infection. Postgrad Med J. 1992;68:143-144.
59. Maertens J. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies. Eur J Haematol. 2007;78:275-282.
60. Maertens J, Meersseman W, Van Bleyenbergh P. New therapies for fungal pneumonia. Curr Opin Infect Dis. 2009;22:183-190.
61. Mahfouz T, Miceli MH, Saghafifar F, Stroud S, Jones-Jackson L, Walker R, Grazziutti ML, Purnell G, Fassas A, Tricot G, Barlogie B, Anaissie E. 18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes. J Clin Oncol. 2005;23:7857-7863.
62. Marinach-Patrice C, Lethuillier A, Marly A, Brossas JY, Gene J, Symoens F, Datry A, Guarro J, Mazier D, Hennequin C. Use of mass spectrometry to identify clinical Fusarium isolates. Clin Microbiol Infect. 2009;15:634-642.
63. Marino E, Gallagher JC. Prophylactic antifungal agents used after lung transplantation. Ann Pharmacother. 44:546-556.
64. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909-917. (Pubitemid 34229758)
65. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med. 2004;350:950-952.
66. Mattiuzzi GN, Alvarado G, Giles FJ, Ostrosky-Zeichner L, Cortes J, Obrien S, Verstovsek S, FaDerl S, Zhou X, Raad, II, Bekele BN, Leitz GJ, Lopez-Roman I, Estey EH. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother. 2006;50:143-147.
67. Mehrad B, Paciocco G, Martinez FJ, Ojo TC, Iannettoni MD, Lynch JP III. Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature. Chest. 2001;119:169-175.
68. Merz WG, Karp JE, Hoagland M, Jett-Goheen M, Junkins JM, Hood AF. Diagnosis and successful treatment of fusariosis in the compromised host. J Infect Dis. 1988;158:1046-1055.
69. Moffatt-Bruce SD. Lung Transplantation. eMedicine.com Web site. May 13, 2009. [http://emedicine.medscape.com/article/429499-overview. Accessed on April 12, 2010.]
70. Murray CK, Beckius ML, McAllister K. Fusarium proliferatum superficial suppurative thrombophlebitis. Mil Med. 2003;168: 426-427.
71. Nelson PE, Dignani MC, Anaissie EJ. Taxonomy, biology, and clinical aspects of Fusarium species. Clin Microbiol Rev. 1994;7:479-504.
72. Neofytos D, Fishman JA, Horn D, Anaissie E, Chang CH, Olyaei A, Pfaller M, Steinbach WJ, Webster KM, Marr KA. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis. 2010;12:220-229. Epub 2010 Jan 25.
73. Nucci M. Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr Opin Infect Dis. 2003;16:607-612.
74. Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management Clin Infect Dis. 2002;35:909-920.
75. Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev. 2007;20:695-704.
76. Nucci M, Anaissie EJ, Queiroz-Telles F, Martins CA, Trabasso P, Solza C, Mangini C, Simoes BP, Colombo AL, Vaz J, Levy CE, Costa S, Moreira VA, Oliveira JS, Paraguay N, Duboc G, Voltarelli JC, Maiolino A, Pasquini R, Souza CA. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer. 2003;98:315-319.
77. Nucci M, Marr KA, Queiroz-Telles F, Martins CA, Trabasso P, Costa S, Voltarelli JC, Colombo AL, Imhof A, Pasquini R, Maiolino A, Souza CA, Anaissie E. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2004;38:1237-1242.
78. Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, Ketchum PA, Finkelman MA, Rex JH, Ostrosky-Zeichner L. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis. 2004;39:199-205. (Pubitemid 38971490)
79. O'Donnell K, Cigelnik E, Casper HH. Molecular phylogenetic, morphological, and mycotoxin data support reidentification of the Quorn mycoprotein fungus as Fusarium venenatum. Fungal Genet Biol. 1998;23:57-67.
80. O'Donnell K, Kistler HC, Cigelnik E, Ploetz RC. Multiple evolutionary origins of the fungus causing Panama disease of banana: concordant evidence from nuclear and mitochondrial gene genealogies. Proc Natl Acad Sci USA. 1998;95:2044-2049.
81. O'Donnell K, Sutton DA, Fothergill A, McCarthy D, Rinaldi MG, Brandt ME, Zhang N, Geiser DM. Molecular phylogenetic diversity, multilocus haplotype nomenclature, and in vitro antifungal resistance within the Fusarium solani species complex. J Clin Microbiol. 2008;46:2477-2490.
82. O'Donnell K, Sutton DA, Rinaldi MG, Magnon KC, Cox PA, Revankar SG, Sanche S, Geiser DM, Juba JH, Van Burik JA, Padhye A, Anaissie EJ, Francesconi A, Walsh TJ, Robinson JS. Genetic diversity of human pathogenic members of the Fusarium oxysporum complex inferred from multilocus DNA sequence data and amplified fragment length polymorphism analyses: evidence for the recent dispersion of a geographically widespread clonal lineage and nosocomial origin. J Clin Microbiol. 2004;42:5109-5120.
83. OPTN: Organ Procurement and Transplantation Network. U. S. Department of Health & Human Services Web site.Ehttp://optn.transplant.hrsa.gov/ organDatasource/about.asp?display= Lung. Accessed on April 12, 2010.
84. Ostrosky-Zeichner L, AlexanDer BD, Kett DH, Vazquez J, Pappas PG, Saeki F, Ketchum PA, Wingard J, Schiff R, Tamura H, Finkelman MA, Rex JH. Multicenter clinical evaluation of the (1[rarrow]3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis. 2005;41:654-659.
85. Pappas PG, AlexanDer BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, Anaissie EJ, Brumble LM, Herwaldt L, Ito J, Kontoyiannis DP, Lyon GM, Marr KA, Morrison VA, Park BJ, Patterson TF, Perl TM, Oster RA, Schuster MG, Walker R, Walsh TJ, Wannemuehler KA, Chiller TM. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50:1101-1111.
86. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46:201-211.
87. Patterson JE. Epidemiology of fungal infections in solid organ transplant patients. Transpl Infect Dis. 1999;1:229-236.
88. Penack O, Rempf P, Graf B, Blau IW, Thiel E. Aspergillus galactomannan testing in patients with long-term neutropenia: implications for clinical management. Ann Oncol. 2008;19:984-989.
89. Perfect JR. Aerosolized antifungal prophylaxis: the winds of change? Clin Infect Dis. 2008;46:1409-1411.
90. Perfect JR, Dodds Ashley E, Drew R. Design of aerosolized amphotericin b formulations for prophylaxis trials among lung transplant recipients. Clin Infect Dis. 2004;39(Suppl 4):S207-210.
91. Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, de la Torre-Cisneros J, Just-Nubling G, Schlamm HT, Lutsar I, Espinel-Ingroff A, Johnson E. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003;36:1122-1131.
92. PflugfelDer SC, Flynn HW Jr, Zwickey TA, Forster RK, Tsiligianni A, Culbertson WW, Mandelbaum S. Exogenous fungal endophthalmitis. Ophthalmology. 1988;95:19-30.
93. Price TH. Granulocyte transfusion in the G-CSF era. Int J Hematol. 2002;76(Suppl 2):77-80.
94. Pujol I, Guarro J, Gene J, Sala J. In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains. J Antimicrob Chemother. 1997;39:163-167.
95. Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G, Kontoyiannis DP. Posaconazole as salvage treatment for invasive fusariosis in patients with unDerlying hematologic malignancy and other conditions. Clin Infect Dis. 2006;42: 1398-1403.
96. Reitz BA, Wallwork JL, Hunt SA, Pennock JL, Billingham ME, Oyer PE, Stinson EB, Shumway NE. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med. 1982;306:557-564.
97. Reuben A, Anaissie E, Nelson PE, Hashem R, Legrand C, Ho DH, Bodey GP. Antifungal susceptibility of 44 clinical isolates of Fusarium species determined by using a broth microdilution method. Antimicrob Agents Chemother. 1989;33:1647-1649.
98. RijnDers BJ, Cornelissen JJ, Slobbe L, Becker MJ, Doorduijn JK, Hop WC, Ruijgrok EJ, Lowenberg B, Vulto A, Lugtenburg PJ, de Marie S. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis. 2008;46: 1401-1408.
99. Rippon JW, Larson RA, Rosenthal DM, Clayman J. Disseminated cutaneous and peritoneal hyalohyphomycosis caused by Fusarium species: three cases and review of the literature. Mycopathologia. 1988;101:105-111.
100. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, Kontoyiannis DP, Walsh TJ. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634-653.
101. Rodriguez CA, Lujan-Zilbermann J, Woodard P, Andreansky M, AdDerson EE. Successful treatment of disseminated fusariosis. Bone Marrow Transplant. 2003;31:411-412.
102. Ruiz-Cendoya M, Marine M, Guarro J. Combined therapy in treatment of murine infection by Fusarium solani. J Antimicrob Chemother. 2008;62:543-546.
103. Ruiz-Cendoya M, Marine M, Rodriguez MM, Guarro J. Interactions between triazoles and amphotericin B in treatment of disseminated murine infection by Fusarium oxysporum. Antimicrob Agents Chemother. 2009;53:1705-1708.
104. Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, Loebenberg D, Black TA, McNicholas PM. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother. 2006;50:2009-2015.
105. SanDer A, Beyer U, Amberg R. Systemic Fusarium oxysporum infection in an immunocompetent patient with an adult respiratory distress syndrome (ARDS) and extracorporal membrane oxygenation (ECMO). Mycoses. 1998;41:109-111.
106. Selleslag D. A case of fusariosis in an immunocompromised patient successfully treated with liposomal amphotericin B. Acta Biomed. 2006;77(Suppl 2):32-35.
107. Seyfarth F, Ziemer M, Sayer HG, Burmester A, Erhard M, Welker M, Schliemann S, Straube E, Hipler UC. The use of ITS DNA sequence analysis and MALDI-TOF mass spectrometry in diagnosing an infection with Fusarium proliferatum. Exp Dermatol. 2008;17:965-971.
108. Silveira FP, Kwak EJ, Paterson DL, Pilewski JM, McCurry KR, Husain S. Post-transplant colonization with non-Aspergillus molds and risk of development of invasive fungal disease in lung transplant recipients. J Heart Lung Transplant. 2008;27:850-855.
109. Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant. 2003;22:258-266.
110. SpaDer TB, Venturini TP, Cavalheiro AS, Mahl CD, Mario DN, Lara VM, Santurio J, Alves SH. In vitro interactions between amphotericin B and other antifungal agents and rifampin against Fusarium spp. Mycoses. 2009;Sep 16. EEpub ahead of print.
111. Spanakis EK, Aperis G, Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis, 2006, 43, 1060-1068.
112. Stanzani M, Tumietto F, Vianelli N, Baccarani M. Update on the treatment of disseminated fusariosis: Focus on voriconazole. Ther Clin Risk Manag. 2007;3:1165-1173.
113. Stelzmueller I, Lass-Floerl C, Geltner C, Graziadei I, Schneeberger S, Antretter H, Mueller L, Zelger B, Singh N, Pruett TL, Margreiter R, Bonatti H. Zygomycosis and other rare filamentous fungal infections in solid organ transplant recipients. Transpl Int. 2008;21:534-546.
114. Sturm AW, Grave W, Kwee WS. Disseminated Fusarium oxysporum infection in patient with heatstroke. Lancet. 1989;1(8644):968.
115. Tezcan G, Ozhak-Baysan B, Alastruey-Izquierdo A, Ogunc D, Ongut G, Yildiran ST, Hazar V, Cuenca-Estrella M, Rodriguez-Tudela JL. Disseminated fusariosis caused by Fusarium verticillioides in an acute lymphoblastic leukemia patient after allogeneic hematopoietic stem cell transplantation. J Clin Microbiol. 2009;47:278-281.
116. Tortorano AM, Prigitano A, Dho G, Esposto MC, Gianni C, Grancini A, Ossi C, Viviani MA. Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy. Antimicrob Agents Chemother. 2008;52:2683-2685.
117. Transplantation Services, Lung Transplantation Program, UPMC, Pittsburgh, PA, USA. University of Pittsburgh Medical Center Web site. [http://www.upmc. com/services/transplantationservices/ typesoftransp lant/lungtransplant/Pages/ default.aspx. Accessed on April 12, 2010.]
118. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335-347.
119. Unilateral lung transplantation for pulmonary fibrosis. Toronto Lung Transplant Group. NEngl J Med. 1986;314:1140-1145.
120. U S. Transplants Performed at Massachusetts General Hospital: January 1, 1988-August 31, 2009. U S. Department of Health & Human Services Web site. [http://optn.transplant.hrsa.gov/latestData/ stateData.asp?type=center. Accessed on April 12, 2010.]
121. Valentine NB, Wahl JH, Kingsley MT, Wahl KL. Direct surface analysis of fungal species by matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun Mass Spectrom. 2002;16: 1352-1357.
122. Veglia KS, Marks VJ. Fusarium as a pathogen. A case report of Fusarium sepsis and review of the literature. J Am Acad Dermatol. 1987;16:260-263.
123. Velasco E, Martins CA, Nucci M. Successful treatment of catheter-related fusarial infection in immunocompromised children. Eur J Clin Microbiol Infect Dis. 1995;14:697-699.
124. Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect. 2004;10(Suppl 1):48-66.
125. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Schuster M, Reboli A, Wingard J, Arndt C, Reinhardt J, Hadley S, Finberg R, Laverdiere M, Perfect J, Garber G, Fioritoni G, Anaissie E, Lee J. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346:225-234. (Pubitemid 34438861)
126. Welham KJ, Domin MA, Johnson K, Jones L, Ashton DS. Characterization of fungal spores by laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom. 2000;14:307-310.
127. Wheeler MS, McGinnis MR, Schell WA, Walker DH. Fusarium infection in burned patients. Am J Clin Pathol. 1981;75:304-311.
128. White PL, Perry MD, Barnes RA. An update on the molecular diagnosis of invasive fungal disease. FEMS Microbiol Lett. 2009;296:1-10.
129. Wickern GM. Fusarium allergic fungal sinusitis. J Allergy Clin Immunol. 1993;92:624-625.
130. Young NA, Kwon-Chung KJ, Kubota TT, Jennings AE, Fisher RI. Disseminated infection by Fusarium moniliforme during treatment for malignant lymphoma. J Clin Microbiol. 1978;7:589-594.
131. Zhang N, O'Donnell K, Sutton DA, Nalim FA, Summerbell RC, Padhye AA, Geiser DM. Members of the Fusarium solani species complex that cause infections in both humans and plants are common in the environment. J Clin Microbiol. 2006;44:2186-2190.